A Randomized, Open Label, Multinational Phase 3 Trail Comparing Amrubibin Versus Topotecan in Patients with Extensive or Limited and Sensative or Refractory Small Cell Lung Cancer after Failure of First Line Chemotherapy
|Effective start/end date||4/1/08 → 4/24/12|
- Celgene Corporation
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.